Highlights from CGT Summit 2025: A Step Forward in Cell & Gene Therapy

The 2nd Global Cell & Gene Therapy (CGT) Summit was held from July 7–9, 2025, in Orlando, Florida, and brought together an exceptional lineup of scientists, clinicians, industry leaders, regulatory authorities, and innovators from around the world. Over three dynamic days, the summit served as a hub for the latest breakthroughs, in-depth scientific exchange, and strategic discussions shaping the future of cell and gene therapy.

Hosted at the Holiday Inn & Suites Across from Universal Orlando™, the event featured a diverse agenda spanning scientific advancements, clinical translation, regulatory pathways, manufacturing innovation, and commercial strategy. With a mix of keynote talks, panel discussions, and networking opportunities, the summit reinforced its growing reputation as a premier platform for thought leadership and partnership-building in the CGT field.

Program Overview

The three-day event, held from July 7–9, 2025, featured a mix of keynote talks, technical sessions, panel discussions, networking breaks, and poster presentations. Each day was dedicated to a core theme, offering a comprehensive look at the latest developments and challenges in the field.

Day 1: July 7, 2025 — Scientific Foundations and Emerging Therapies

· Session I: Advancements in Cell and Stem Cell-based Therapies

· Session II: Advancing Cell-Based Immunotherapies: CAR-T, TCR-T and Beyond

· Session III: Cell and Gene Therapy Research Advancements: From Basics to Clinical Applications

· Session IV: Gene Therapy: Methods, Strategies & Clinical Applications

· Poster Presentations & Networking Drinks

Day 1 set the stage with foundational science, showcasing translational research in stem cells, CAR-T/TCR-T, and gene therapy platforms—from early discovery to clinical readiness.

Day 2: July 8, 2025 — Manufacturing, Technology, and Scalability

· Session V: Scaling Up CGT: Manufacturing Innovation, Commercialization Strategies & Global Accessibility

· Session VI: Optimizing AAV Manufacturing: Engineering, Processing, Analysis and Quality Control

· Panel Discussion I: Breaking Barriers in Viral Vectors & CAR-T and Gene Therapy Manufacturing: Innovations for Scalability and Affordability

· Networking Dinner*

Day 2 was packed with technical deep dives and innovation showcases in AAV manufacturing, vector engineering, and platform scalability—culminating in a powerful panel dialogue.

Day 3: July 9, 2025 — Regulation, Partnerships, and Future Roadmaps

· Session VII: Regulatory Landscape and Commercialization Strategies

· Panel Discussion II: Collaborative Approaches: Industry-Academia Partnerships in CGT Manufacturing

The final day explored CGT’s regulatory environment and commercialization outlook, emphasizing collaboration between stakeholders across academia, industry, and government.

Exhibitor Spotlight

The CGT Summit 2025 exhibition space served as a dynamic hub of innovation and collaboration.

This year’s esteemed exhibitors included:

· Minaris Advanced Therapies – Proud Silver Sponsor of the summit, Minaris brought deep knowledge in analytical development, release testing, and regulatory compliance, critical for advancing CGT products from bench to bedside.

· PromoCell – Leading provider of human primary cells and cell culture systems, essential for preclinical and translational CGT research.

· QIAGEN – Demonstrated their genomic and sample preparation technologies, supporting molecular diagnostics, gene therapy development, and quality assurance.

· Astorium – Presented cutting-edge automation solutions tailored for GMP-compliant manufacturing of advanced therapies.

· BatchLine – Introduced digital batch record platforms designed to streamline documentation, increase compliance, and support CGT scalability.

· Parker Hannifin – Showcased bioprocessing hardware and fluid management systems that enhance CGT production consistency and control.

· CuraScript SD – Provided expertise in specialty distribution and logistics services to support secure, efficient delivery of sensitive CGT products.

· MaxCyte – Highlighted their non-viral cell engineering platform, offering scalable electroporation systems for clinical and commercial use.

· Facet Life Sciences – Offered regulatory consulting and submission strategy, helping companies navigate CGT product approval with precision.

· PL BioScience – Showcasing xeno-free human platelet lysates to support robust and GMP-compliant cell expansion.

· Excellos – Providing integrated donor tissue sourcing, cell processing, and GMP manufacturing services to streamline CGT workflows.

The exhibit hall was a cornerstone of the summit, buzzing with live demonstrations, interactive booths, and meaningful conversations

Conclusion

The 2nd Global Cell & Gene Therapy Summit 2025 in Orlando was more than just a conference—it was a dynamic meeting ground for the brightest minds shaping the future of CGT. From scientific discovery and clinical translation to manufacturing scale-up and commercialization, the summit provided a holistic view of the challenges and opportunities in this fast-evolving space.

We thank all speakers, participants, and partners for making CGT Summit 2025 a success—and we look forward to welcoming you to the CGT Summit 2026, taking place July 6–8, 2026, in Wakefield, MA!